Work

AR-V7 and treatment selection in advanced prostate cancer: are we there yet?

Year: 2018

Type: editorial

Abstract: Castration-resistant prostate cancer (CRPC) remains a lethal disease, despite marked improvements in outcomes over the past decade with incorporation of novel androgen-receptor signaling inhibitors (ARSi), taxane-based chemotherapies, sipuleucel-T and radium-223 (1). However, treatment sequencing is still based on subjective clinical parameters and physician experience, which remains a major challenge. Moreover, despite the identification of several prognostic markers, prospectively validated biomarkers used for treatment selection (that may guide oncologists in choosing the right treatment option for their patients at the right time) are still lacking.

Source: Precision Cancer Medicine

DOI: 10.21037/pcm.2018.09.01

Authors: Diogo A. Bastos, Emmanuel S. Antonarakis

Institutions: Hospital Sírio-Libanês, Johns Hopkins University, Johns Hopkins Medicine, Sidney Kimmel Comprehensive Cancer Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid